How Does Mounjaro Work? Mechanism, Dosing, and Ozempic Comparison
Mounjaro (tirzepatide) is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1, while drugs like Ozempic act on GLP-1 alone. Through GLP-1 signaling it stimulates insulin release, suppresses glucagon, slows the stomach, and cuts appetite; its half-life is about 5 days.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Mounjaro (tirzepatide) is a once-weekly injection that works by copying two gut hormones at the same time. It selectively binds to and activates both the GIP receptor and the GLP-1 receptor — the same targets that the natural hormones GIP and GLP-1 use [2]. Drugs like Ozempic (semaglutide) activate only the GLP-1 receptor, which is why Mounjaro is called a dual agonist rather than a pure GLP-1 drug [2, 6].
Through GLP-1 receptor signaling, these drugs stimulate insulin secretion, suppress glucagon, slow gastric emptying, and enhance satiety so people eat less [6]. GIP, the second hormone Mounjaro copies, also enhances glucose-stimulated insulin secretion after eating [6]. Mounjaro received initial U.S. approval in 2022 [1, 2], and the molecule was developed by Eli Lilly under the research code LY3298176 [3].
What is Mounjaro?
Mounjaro is the brand name for tirzepatide injection, given as a shot under the skin [1]. The label classifies it as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist [1, 2]. It is a first-in-class, single-molecule dual GIP receptor and GLP-1 receptor agonist — one molecule that activates both receptors, not two drugs combined [2]. It is injected once weekly [1, 2].
The molecule itself is an amino acid sequence with a C20 fatty diacid moiety attached [2]. That fatty component enables the drug to bind to albumin in the blood, which prolongs its half-life and allows once-weekly dosing [2]. Its mean half-life is about 5 days [6]. It was designed from the start as a fatty acid-modified peptide for once-weekly subcutaneous administration [3].
Is Mounjaro a GLP-1 drug?
Partly. Mounjaro activates the GLP-1 receptor, so it shares the core actions of selective GLP-1 receptor agonists like Ozempic (semaglutide) [2, 6]. But it also activates the GIP receptor, which selective GLP-1 drugs do not [2, 6]. GIP and GLP-1 are the two known incretins — gut hormones released after eating that enhance glucose-stimulated insulin secretion [6].
Both receptor types sit in many organs and tissues throughout the body, with some overlapping and some non-overlapping functions [2]. Researchers posit that this spread of receptors contributes to the results seen with tirzepatide in clinical trials [2].
How does tirzepatide lower blood sugar?
In cell studies, tirzepatide activated both GIP and GLP-1 receptor signaling [3]. In mice, it produced glucose-dependent insulin secretion and improved glucose tolerance by acting on both receptors [3].
In people with type 2 diabetes, a 4-week phase 1b study found that tirzepatide 10 mg and 15 mg significantly reduced fasting serum glucose compared with placebo: the least-squares mean differences were −49.12 mg/dL (95% CI −78.14 to −20.12) for 10 mg and −43.15 mg/dL (95% CI −73.06 to −13.21) for 15 mg [3]. Across the whole phase 1 program, 142 human subjects received at least one dose of LY3298176, dulaglutide, or placebo [3].
In a phase 2b study of patients with type 2 diabetes, tirzepatide showed superior reduction of both HbA1c and body weight compared with dulaglutide, a selective GLP-1 receptor agonist [6].
On the question of low blood sugar: the label’s hypoglycemia warning addresses concomitant use of Mounjaro with an insulin secretagogue (such as a sulfonylurea) or with insulin, which may increase the risk of hypoglycemia, including severe hypoglycemia; reducing the dose of those other medicines may be necessary [1].
What does Mounjaro do to the stomach, and why does that effect fade?
Mounjaro delays gastric emptying, and the label notes this can affect how oral medications are absorbed [1].
Researchers measured this effect directly using acetaminophen absorption in a phase 1, 4-week multiple-dose study [6]. In humans, a single dose of tirzepatide delayed gastric emptying at doses of 5 mg or higher in people with type 2 diabetes, and 4.5 mg or higher in people without it [6].
The effect shrinks with continued use. In healthy participants, the delay diminished after multiple doses of tirzepatide or dulaglutide [6]. In participants with type 2 diabetes on escalation schedules of 5/5/10/10 mg or 5/5/10/15 mg, a residual delay in gastric emptying was still observed after multiple doses [6].
Animal work points the same direction, though it involved mice, not people. In mice, tirzepatide delayed gastric emptying to a similar degree as semaglutide, but that acute effect was abolished after 2 weeks of treatment [6]. A long-acting GIP analog alone had no effect on gastric emptying in mice, and it did not change GLP-1’s effect on it either — GIP has no known impact on gastric emptying [6].
The study’s conclusion: tirzepatide’s activity on gastric emptying is comparable to that of selective GLP-1 receptor agonists, not greater [6]. More broadly, the magnitude of the gastric-emptying effect — unlike the effects on glycemic control or appetite — attenuates with prolonged GLP-1 exposure [6].
What does the GIP half add beyond GLP-1?
This is the part scientists are still working out. What is published so far points to a few possibilities, several of them from animal research.
In mice given chronic dosing, tirzepatide decreased body weight and food intake to a significantly greater degree than a GLP-1 receptor agonist [3]. In people, tirzepatide has produced greater weight loss than GLP-1 receptor agonism alone in obesity and type 2 diabetes [10].
A study from Lilly Research Laboratories, conducted in obese mice, concluded that GIP receptor agonism mediates weight-independent insulin sensitization by tirzepatide — meaning the GIP arm improved insulin sensitivity in a way that was not just a byproduct of weight loss [5]. That evidence comes from mouse research; it has not been shown in humans. A 2024 Cell Metabolism paper reported that tirzepatide modulates how fat cells handle nutrients through long-acting GIP receptor activation [8].
There is also an unresolved puzzle in the field: both GIP receptor agonism and GIP receptor antagonism appear to add weight loss on top of GLP-1 receptor agonism, and the mechanism behind that paradox is not understood [7, 10].
Where in the brain does GIP act on appetite?
All of the findings below come from mouse experiments, not human studies [10].
GIP receptor agonists decrease food intake and body weight in mice through a pathway involving Gipr-expressing GABAergic neurons, a population of which is located in the area postrema, part of the brainstem [10]. A 2026 Nature Metabolism study knocked out Gipr in either the area postrema or the hypothalamus of mice. Area postrema knockout mice showed a reduced response to the appetite-suppressing effects of acyl-GIP and partial protection from diet-induced obesity [10].
Hypothalamic knockout mice, by contrast, showed normal appetite suppression from acyl-GIP but enhanced weight loss on the GLP-1 drug liraglutide, and knocking out hypothalamic Gipr abolished the synergy seen when a GIP receptor antagonist was combined with liraglutide [10]. Chemogenetic activation of Gipr neurons in either the hypothalamus or hindbrain decreased food intake in mice [10].
What about the GIP agonism-versus-antagonism debate?
Some researchers argue the opposite approach — blocking the GIP receptor instead of activating it — could also aid weight loss. A 2025 Counterpoint commentary in the journal Diabetes, authored by researchers arguing the case for GIP receptor antagonism, laid out that position; the journal published it alongside an opposing article arguing for GIP receptor agonism, part of an organized debate on the question [7].
That commentary states that metabolic benefits have been observed with both GIP receptor agonism and antagonism, and that the mechanism underlying this apparent paradox remains unknown [7]. It reports that global and central nervous system knockout of the GIP receptor protects mice fed a high-fat diet from obesity and insulin resistance [7]. Human genome-wide association studies correlate lower BMI with GIP receptor genetic variants that have reduced function [7]. In mouse and monkey pharmacology studies, GIP receptor antagonism enhanced GLP-1-induced weight reduction, and a phase 1 study provided proof of principle that such effects extend to humans [7].
None of this changes how Mounjaro itself works — it activates the GIP receptor — but it explains why the science of GIP is still actively debated [7, 10].
How is Mounjaro dosed and injected?
The following is label text, not a suggestion for any individual — dosing decisions belong with a prescriber [1].
The recommended starting dosage is 2.5 mg injected under the skin once weekly [1]. If additional glycemic control is needed, the dose is increased in 2.5 mg increments after at least 4 weeks on the current dose [1]. The maximum dosage is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older [1]. The label states the purpose of this schedule is to reduce the risk of gastrointestinal adverse reactions [1].
| Label rule | Detail |
|---|---|
| Starting dosage | 2.5 mg subcutaneously once weekly [1] |
| Escalation | 2.5 mg increments after at least 4 weeks on the current dose, only if additional glycemic control is needed [1] |
| Maximum, adults | 15 mg once weekly [1] |
| Maximum, pediatric (10 years and older) | 10 mg once weekly [1] |
| Missed dose window | Within 4 days (96 hours); after that, skip and resume on the scheduled day [1] |
| Changing dosing day | Allowed if at least 3 days separate two doses [1] |
Mounjaro can be administered at any time of day, with or without meals [1]. Injection sites are the abdomen, the thigh, or the back of the upper arm (the upper arm site requires another person to inject), and sites should be rotated with each dose [1].
It comes as a single-dose pen or vial in strengths of 2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL [1]. It also comes as a multi-dose vial or single-patient-use KwikPen in strengths of 10, 20, 30, 40, 50, or 60 mg per 2.4 mL, each delivering four doses of 2.5 to 15 mg per 0.6 mL [1]. A KwikPen must never be shared between patients, even with a new needle [1].
What is Mounjaro approved to treat?
Mounjaro’s label covers two uses. First, as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes [1]. Second, to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes at high risk for these events [1]. The cardiovascular indication was added to the label in 08/2026, and the label includes a Cardiovascular Outcomes Trial section covering adults with type 2 diabetes and established cardiovascular disease [1]. The pediatric indication was added in 12/2025 [1].
Mounjaro is not approved for weight loss or for sleep apnea. The tirzepatide approvals for weight reduction (2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (2024) belong to a separate product, Zepbound, which contains the same medicine under a different brand name with its own approved uses [2].
What are the main safety concerns?
Mounjaro carries a boxed warning. Tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both male and female rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent tumors has not been determined [1].
Because of that, Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and also in people with known serious hypersensitivity to tirzepatide or its excipients [1].
The most common adverse reactions, reported in at least 5% of patients, are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain [1]. In the phase 1 program, the most frequent side effects were gastrointestinal — vomiting, nausea, decreased appetite, diarrhea, and abdominal distension — and were dose-dependent and mild to moderate in severity [3].
The label’s warnings and precautions include acute pancreatitis; hypoglycemia when combined with insulin secretagogues or insulin; serious hypersensitivity reactions including anaphylaxis and angioedema; acute kidney injury from volume depletion; severe gastrointestinal reactions (Mounjaro is not recommended in severe gastroparesis); monitoring for diabetic retinopathy progression; acute gallbladder disease; and pulmonary aspiration during general anesthesia or deep sedation [1].
Females using oral contraceptives are advised on the label to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation [1]. Based on animal studies, Mounjaro may cause fetal harm in pregnancy [1]. Suspected adverse reactions can be reported to Eli Lilly at 1-800-545-5979 or the FDA at 1-800-FDA-1088 [1].
Mounjaro vs. Ozempic: how do their mechanisms differ?
The core difference is receptor count. Semaglutide and other selective GLP-1 receptor agonists act at one receptor; tirzepatide activates two [2, 6].
| Feature | Mounjaro (tirzepatide) | Selective GLP-1 RAs (e.g., semaglutide) |
|---|---|---|
| Receptors activated | GIP and GLP-1 [2, 6] | GLP-1 only [2, 6] |
| Gastric emptying | Delays it; effect diminishes with continued dosing; comparable to selective GLP-1 RAs [1, 6] | Delays it; effect attenuates with prolonged exposure [6] |
| Head-to-head data | Superior HbA1c and weight reduction vs. dulaglutide in phase 2b [6] | Dulaglutide served as the comparator and phase 1 positive control [3, 6] |
| Weight loss vs. GLP-1 alone | Greater weight loss than GLP-1R agonism alone reported in obesity/T2D [10] | — |
Two cautions on comparing the drugs. The published head-to-head trial listed here compared tirzepatide with dulaglutide, not semaglutide [6]. And the gastric-emptying study concluded tirzepatide’s effect on the stomach is comparable to selective GLP-1 receptor agonists, not greater [6]. The published record does not show that Mounjaro is stronger or safer than semaglutide beyond what these cited studies support.
Sources
- Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information.
- Diabetes Therapy. Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. November 6, 2025.
- PubMed Central. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
- The Lancet Diabetes & Endocrinology. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes.
- Journal of Clinical Investigation. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
- Diabetes, Obesity and Metabolism. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. 2020.
- Diabetes. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale. August 2025.
- Cell Metabolism. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
- Cell Metabolism. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
- Nature Metabolism. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
- Diabetes, Obesity and Metabolism. A long-acting GIP receptor agonist improves the gastrointestinal tolerability of GLP-1 receptor agonist therapy. 2024.
- US Food and Drug Administration. Clinical pharmacology review for Mounjaro (tirzepatide), NDA 215866.
- PNAS. Structural determinants of dual incretin receptor agonism by tirzepatide.
- US Food and Drug Administration. Supplement approval letter for Mounjaro (tirzepatide) injection, NDA 215866/S-044 and S-045.
- Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information.
- CPT: Pharmacometrics & Systems Pharmacology. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. 2024.
- PR Newswire. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. August 28, 2026.
- New England Journal of Medicine. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
- PubMed. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Frequently asked questions
Do Mounjaro and Ozempic work the same way?
They overlap but are not the same. Both activate the GLP-1 receptor, which drives insulin release, glucagon suppression, slower stomach emptying, and satiety. Mounjaro also activates the GIP receptor, a second gut-hormone target that Ozempic does not activate [2, 6]. That dual action is the main mechanistic difference between the two drugs.
Why does Mounjaro start at 2.5 mg, and when can the dose go up?
The label sets a starting dosage of 2.5 mg once weekly. The dose goes up only if additional glycemic control is needed, and only in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly in adults. The label states this schedule exists to reduce the risk of gastrointestinal adverse reactions. Any dose change is a decision for the prescriber.
What happens if a weekly dose is missed?
Per the label, a missed dose should be given as soon as possible within 4 days (96 hours). If more than 4 days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day, then the weekly schedule resumes. The dosing day can be changed as long as at least 3 days separate two doses.
Can Mounjaro cause low blood sugar on its own?
The label's hypoglycemia warning addresses combining Mounjaro with an insulin secretagogue, such as a sulfonylurea, or with insulin, which may increase the risk of hypoglycemia, including severe episodes; reducing the dose of those other medicines may be necessary. The supplied label text frames that risk in the context of those concomitant medicines.
Is nausea a common side effect of Mounjaro?
Yes. Nausea is one of the most common adverse reactions, reported in at least 5% of patients, along with diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. In phase 1 studies, gastrointestinal side effects were dose-dependent and mild to moderate. How long side effects last for any individual is a question for that person's provider.
Is Mounjaro approved for weight loss?
No. Mounjaro's label covers glycemic control in type 2 diabetes and, since 08/2026, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. The tirzepatide approvals for weight reduction (2023) and obstructive sleep apnea (2024) belong to a separate product, Zepbound.
Does Mounjaro protect the heart?
The label states Mounjaro is indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes at high risk for these events. That indication was added in 08/2026, and the label includes a Cardiovascular Outcomes Trial section in adults with type 2 diabetes and established cardiovascular disease.
Can children take Mounjaro?
Yes, for type 2 diabetes. The label includes pediatric patients 10 years of age and older as an adjunct to diet and exercise for glycemic control, an indication added in 12/2025. The maximum dose in pediatric patients is 10 mg once weekly, lower than the 15 mg adult maximum. Dosing decisions rest with the child's prescriber.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.